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Abstract 
Objective To assess adherence to guidelines for the 
management of Parkinson’s disease (PD) by healthcare 
professionals at the Rehabilitation Hospital Karin Grech 
(RHKG) in Malta.
Method Retrospective and current data of inpatient 
medical records at RHKG was collected for 90 patients. 
Guidelines available at the hospital were reviewed and a 
comparison was compiled. Data collected and the compiled 
guidelines were used to assess the level of adherence of 
treatment decisions to guidelines. Analysis of data was carried 
out using Microsoft Office Excel® 2007 and SPSS® version 17.0.
Key findings Results show generally high 
adherence to published guidelines. Out of 22 patients 
started on co-careldopa therapy at the hospital, 16 had 
treatment decisions which adhered to guidelines. In the 
case of co-beneldopa, ropinirole and trihexyphenidyl 
(benzhexol) treatment, all patients had their treatment 
decisions implemented according to guidelines. 
Conclusion Healthcare professionals at RHKG are 
aware of the presence of treatment guidelines. The adherence 
of their treatment decisions to guidelines indicates a good 
quality of care. Frequent assessment of the level of adherence 
to guidelines using similar studies will ensure optimisation of 
treatment.
Keywords Parkinson’s disease, management 
guidelines, adherence, prescribing trends.
Introduction
Parkinson’s disease (PD), historically known as ‘the shaking 
palsy’1 has become the second most common progressive 
neurodegenerative disorder after Alzheimer’s disease.2 
A systematic review of the worldwide prevalence and 
incidence of PD, conducted by a thorough literature 
review of  epidemiological studies from 1965 to 2010 
concluded that PD prevalence and incidence increase with 
advancing age.3 There are many reasons for a decreased 
quality of life in PD patients including decreased mobility, 
falls, sleep disturbances, social embarrassment, which 
consequently affects patient’s communication, dyskinesia 
and fluctuation.4
Levodopa is considered the gold standard therapy and 
remains the most commonly used drug in PD since its first 
use 40 years ago.5 Although levodopa is very effective in 
improving both bradykinesia and rigidity, its use is often 
delayed to avoid early development of motor fluctuations 
and dyskinesia, which will establish a source of disability. 
Other medications that are considered in the treatment 
of PD include dopamine receptor agonists, monoamine 
oxidase-B inhibitors, catechol-o-methyl transferase 
inhibitors and amantadine. Although recommendations for 
the use of such medications differ between guidelines, yet 
the consultation of such evidence-based guidelines in any 
healthcare setting is considered of paramount importance 
to help healthcare professionals optimise management of 
PD patients.
The aims of this study were to compile a comparison of 
guidelines for PD treatment, to assess prescribing patterns 
of antiparkinsonian medications at RHKG and to investigate 
whether PD treatment decisions adhere to the compiled 
guidelines.
gUIDELINE COMPARISON AND ASSESSMENT OF 
PRESCRIbINg TRENDS IN PARKINSON’S DISEASE
Asmaa Abdul-Aziz, Marise Gauci, Lilian M. Azzopardi, Maresca Attard Pizzuto, Anthony Serracino-Inglott
Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida
Corresponding author: Asmaa Abdul-Aziz
E-mail: asmaa.m.abdulaziz@gmail.com
26
Method
Patients suffering from PD were identified from pharmacy 
patient profiles in the case of inpatients and directly from 
clinical notes in the case of patients attending day clinics. 
Retrospective and current data obtained included age, 
gender, reason for referral, drug history, treatment changes, 
pharmaceutical care issues and discharge medication. 
The study was adapted from similar work undertaken by 
Schroder et al (2010).6 
The study design involved two processes; a theoretical 
and a practical approach. In the theoretical approach, 
the guidelines generally referred to at RHKG were 
identified, namely the National Institute for Health and 
Clinical Excellence (NICE) guidelines7 and the Scottish 
Intercollegiate Guidelines Network (SIGN) guidelines.8 
A review and comparison of the latest version of these 
guidelines for PD was compiled. The practical approach 
involved data collection and assessment of the level of 
adherence of prescribing trends to guidelines (Table 1). The 
criteria of assessment included a dosing parameter in which 
doses of prescribed antiparkinsonian medications were 
compared to the dosing parameters in the British National 
Formulary.9 
Data collected was further classified according to whether 
patients were taking antiparkinsonian drugs prior to 
admission according to their drug history.
Results
Ninety patients were included in the study. The mean age 
of patients was 78 years. These patients were classified into 
two groups: the no drug history group, those patients who 
had no drug history of antiparkinsonian drugs on admission 
(n=26), and the drug history group, patients who were using 
antiparkinsonian drugs on admission (n=64).
For the 26 patients who had no drug history and were 
admitted to RHKG with symptoms of parkinsonism, 22 
patients were started on co-careldopa, 1 patient was started 
on ropinirole as monotherapy and 3 patients were not 
started on any drug therapy. Adherence to guidelines was 
assessed by evaluating method of initiation of treatment 
and dose management. For the 22 patients started on 
co-careldopa, the introduction of co-careldopa treatment 
was according to guidelines for 16 patients whereas in the 
remaining 6 patients, patients were started on a low dose of 
55 mg twice daily (Figure 1).
For patients admitted with a drug history of antiparkinsonian 
agents, 54 patients were taking co-careldopa, 9 patients 
were taking co-beneldopa of which 1 patient was taking 
also trihexyphenidyl (benzhexol), and 1 patient was taking 
ropinirole as monotherapy. Of the 54 patients taking 
co-careldopa, 8 were also taking ropinirole. Assessment of 
adherence to guidelines was evaluated by assessing dose 
management (Table 2).
Table 1: Sample of data collection tables
Patient
number
Age Year
Reason for 
referral
Drug history
Treatment 
changes
Treatment 
on discharge
1 67
2010
increased 
stiffness + 
tremors
co-careldopa 
110mg three 
times daily
increased to 
110mg three 
times daily + 
55mg at night 
→ after 1 week 
increased to 
110mg four 
times daily
co-careldopa 
110mg four 
times daily
2011
decreased 
mobility + 
decreased  
independence 
in activities of 
daily living and 
dizziness
co-careldopa 
110mg  four 
times daily
remained on 
co-careldopa 
four times daily
co-careldopa 
110mg four 
times daily
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Figure 1: Adherence to guidelines for co-careldopa
Co-careldopa was the drug that was most frequently 
included in the drug treatment for both groups. There was 
100% adherence to guidelines for dose adjustments of 
patients who were already on the drug and 73% adherence 
was identified for patients who were started on the drug 
during hospitalisation (Figure 1). It is worth noting that the 
non-adherence was due to a lower dose being started and 
this could be explained due to cautionary aspects which 
the clinical team were considering when managing the 
individual patients.
Discussion
This study showed a high overall level of adherence to 
PD guidelines. Initial results show that PD treatment is 
dominated by levodopa, followed by the dopamine agonist 
ropinirole. The combination of levodopa and dopamine 
agonists was also observed in many patients. Patients 
in this study were not classified according to functional 
impairment grades, as it was not possible to use this 
indication as an assessment criterion.  
Drug Changes to treatment (number of patients)
Co-careldopa (n=54)
Dose changes according to guidelines (39)
Stopped treatment (9)
No change (6)
Co-beneldopa (n=9)
Dose changes according to guidelines (8)
No change (1)
Ropinirole (n=9)
Dose changes according to guidelines (6)
Stopped treatment (3)
Trihexyphenidyl (Benzhexol) (n=1) Stopped teatment (1)
Table 2: Drug therapy amendments for patients admitted with antiparkinsonian drugs (n=64)
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Another limitation to the study was that information was 
collected only from the pharmacy patient profiles with no 
involvement of the clinical team to justify non-adherence 
to guidelines. In clinical practice, guidelines should be 
perceived as the standards of practice which are adopted 
within a culture of allowing professional judgement by 
the clinical team. Such deviations from standards need to 
be justified and documented in the patient profile.  The 
pharmacist intervention in the clinical team becomes 
especially valuable in managing and co-ordinating 
these deviations which are normally warranted due to 
co-morbidities and other drug therapies.
Conclusion
Studies that assess the level of adherence of treatment 
decisions to evidence-based guidelines are useful because 
they can be used to identify where pharmacist intervention 
is required to rationalise drug therapy and where pharmacist 
intervention is valuable so as to manage justified deviations 
from the guidelines.  
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